20240043386. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use simplified abstract (AbbVie Global Enterprises Ltd.)
Contents
- 1 Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Original Abstract Submitted
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
Organization Name
AbbVie Global Enterprises Ltd.
Inventor(s)
Andrew Bogdan of Evanston IL (US)
David J. Hardee of Vernon Hills IL (US)
Timothy R. Hodges of Milwaukee WI (US)
Henry Korman of Vernon Hills IL (US)
Huan-Qiu Li of Wilmette IL (US)
Michael R. Schrimpf of Grayslake IL (US)
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240043386 titled 'Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
Simplified Explanation
The abstract of the patent application states that the invention relates to compounds and their pharmaceutically acceptable salts, pharmaceutical compositions containing these compounds, and methods of treating cystic fibrosis using these compounds.
- The patent application is about compounds and their salts that have specific values as defined in the specification.
- The compounds can be used to treat cystic fibrosis.
- The invention also includes pharmaceutical compositions that contain these compounds.
- The patent application describes methods of administering the compounds to treat cystic fibrosis.
Potential Applications
The potential applications of this technology include:
- Treatment of cystic fibrosis: The compounds described in the patent application can be used as a potential treatment for cystic fibrosis, a genetic disorder that affects the lungs and other organs.
Problems Solved
This technology solves the following problems:
- Lack of effective treatments for cystic fibrosis: Cystic fibrosis is a complex disease with limited treatment options. The compounds described in the patent application offer a potential solution for treating this condition.
Benefits
The benefits of this technology are:
- Improved treatment options: The compounds and pharmaceutical compositions described in the patent application provide new treatment options for cystic fibrosis patients.
- Potential for better patient outcomes: By targeting the underlying cause of cystic fibrosis, this technology has the potential to improve patient outcomes and quality of life.
Original Abstract Submitted
wherein rhas any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
